{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 54 of 169', 'immediate drug reactions for a minimum of 2 hours with vital signs taken every 30 minutes or', 'until stable, whichever is later. Vital signs will be documented in the eCRF.', 'As with any antibody, allergic reactions to dose administration are possible. The World', 'Allergy Organization has categorised anaphylaxis into 2 subgroups: allergic anaphylaxis', '(mediated by an immunologic mechanism) and nonallergic anaphylaxis (which has a', 'nonimmunologic cause) (31). The clinical criteria for defining anaphylaxis for this trial are', 'listed in Appendix 6 (35). Appropriate drugs, such as epinephrine, antihistamines,', 'corticosteroids, etc., and medical equipment to treat acute anaphylactic reactions must be', 'immediately available at trial sites, and trial personnel should be trained to recognise and', 'respond to anaphylaxis according to local guidelines.', 'If an anaphylactic reaction occurs, a blood sample will be drawn from the subject as soon as', 'possible after the event, at 60 minutes 30 minutes after the event, and at discharge for', 'analysis of serum tryptase at the central laboratory.', 'Conditions requiring IMP administration rescheduling', 'If any of the following should occur, the investigator should reschedule the visit and IMP', 'should not be administered until the rescheduled visit:', 'The subject has an intercurrent illness, that in the opinion of the investigator', 'may compromise the safety of the subject in the trial (e.g., viral illnesses).', 'The subject is febrile (defined as >38\u00b0C;100.4\u00b0F) within 72 hours prior to', 'IMP administration.', 'If the trial visit cannot be rescheduled in order to maintain minimum of 7 days to subsequent', \"dose, the sponsor's medical expert should be contacted.\", 'Home-use', 'Subjects transferring to open-label treatment will have the option to self-administer', 'tralokinumab - or have tralokinumab administered by a caregiver - in their home after', \"training and at the investigator's discretion (selected countries only). Subjects who do not\", 'want to self-inject may have the staff at the trial site administer all the injections at the trial', 'site.', 'Subjects who are found eligible for home-use will have to provide additional informed', 'consent and home-use will only commence after 3 doses of tralokinumab have been', 'administered at the trial site (i.e., starting no earlier than Week 22, see Section 7.1 and the SoP', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 55 of 169', '[Panel 4]). Home-use will start no later than Week 50 (this also applies for subjects in the', 'short-term extension).', 'Prior to self-administration at home, the individual who will be administering the injections', '(i.e., the subject and/or the caregiver) will receive proper training (that is, at 3 dosing visits', 'during open-label treatment after additional consent has been obtained) in SC injection', 'technique and on procedures to be followed in the event of an emergency during or following', 'home-use of tralokinumab. This training will be conducted by the unblinded HCP.', 'The subject and/or the caregiver must also undertake SC administration under HCP', \"supervision on one or more occasions such that the HCP is satisfied with the individual's\", 'understanding and confidence of the procedure.', 'Subjects or their caregivers will only self-administer tralokinumab at home every 4 weeks,', 'i.e., in weeks where no efficacy and safety assessments are scheduled (Panel 4 and Panel 5;', 'see also Section 9.9.3). Where trial visits with efficacy and safety assessments are scheduled', '(every 4 weeks), tralokinumab injections will be administered at the trial site, preferably by', 'the subject or their caregiver, alternatively by the unblinded HCP, when all assessments have', 'been completed.', 'At each trial visit it will be recorded in the eCRF whether tralokinumab was administered by', 'the subject or the unblinded HCP.', '9.3 Treatment assignment', 'Subjects who have been found to comply with all the inclusion criteria and not to violate any', 'of the exclusion criteria will be randomised at baseline (Day 0) to receive treatment with', 'either tralokinumab or placebo in the initial treatment period. Treatment assignment will be', 'pre-planned according to a computer-generated randomisation schedule in a 3:1 ratio', '(tralokinumab:placebo) stratified by region (North America, Japan, and Europe) and baseline', 'disease severity (IGA 3 or 4).', 'Subjects found to be eligible for maintenance treatment at Week 16 will be re-randomised to', 'the maintenance treatment period in a 2:2:1 ratio (tralokinumab Q2W:tralokinumab', 'Q4W:placebo) stratified by region and IGA response at Week 16 (IGA 0/1 or IGA>1).', 'Subjects randomised to placebo in the initial treatment period who achieve a clinical response', 'at Week 16 (IGA 0/1 or EASI75) will continue to receive placebo Q2W in the maintenance', 'treatment period.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}